News >

Immunotherapy Continues to Excite in NSCLC

Angelica Welch
Published: Thursday, Oct 12, 2017

Lawrence E. Feldman, MD

Lawrence E. Feldman, MD
Immunotherapy has excited researchers in the field of oncology over the past few years, and a portion of patients with lung cancer have had significant benefits from this therapeutic option.

In an interview during the meeting, Feldman, associate professor, Section of Hematology/Oncology, College of Medicine, the University of Illinois Hospital and Health System, discussed first- and second-line therapy with checkpoint inhibitors in NSCLC, and the promise that emerging combinations could have on the field.

OncLive: Can you discuss your presentation on checkpoint inhibitors in NSCLC?

Feldman: I was asked to speak on first- and second-line immunotherapy in lung cancer, as well as third-line and beyond. I reviewed the various trials that led to the FDA approval of first-line therapy, such as pembrolizumab in patients who express more than 50% of PD-L1 expression on their tumors.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication